Capital Flow Monitor · Sponsors · CIK 1955319
Nexo Therapeutics, Inc.
11757 W. KEN CARYL AVENUE, LITTLETON, CO, 80127-3719 · 303-868-6790
Biotechnology · Corporation· inc. DELAWARE true 2022
Fit score
—
Offering
$60.0M
Sold
$60.0M
% sold
100.0%
Investors
7
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-03-27 | D/A ·current | 506(b) | $60.0M | $60.0M | 100.0% | 7 | EDGAR ↗ |
| 2025-09-17 | D/A | 506(b) | $60.0M | $52.5M | 87.5% | 7 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
-
Andrew Phillips — Executive Officer / Director, Littleton, CO
2 other raises
- LiquidX, Inc. $4.6M of $5.7M · 80.6%
- Kestrel Therapeutics Inc. $5.0M of $10.0M · 50.0%
- Ali Behbahani — Director, Littleton, CO
- Carlo Rizzuto — Director, Littleton, CO
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.